Entrada Therapeutics
Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.
$7.00
After-hours close+0.02 (+0.29%)
At close$6.98(−3.99%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 75.44%29.28M sharesInsiders 9.98%3.87M sharesOther 14.58%5.66M shares
Shares outstanding 38.82M · Float 22.21M · 57.2% free float
Institutions13F, as of Jun 30, 2026
130 holders · 29.28M shares · 29 new positions · 84 increased · 30 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 5.07M | 13.07% | 0 | Aug 14, 2026 |
| 5Am Venture Management, LLC | 4.06M | 10.45% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 2.58M | 6.65% | +224.5K | Aug 7, 2026 |
| Merck & Co., Inc. | 1.74M | 4.48% | +1.74Mnew | Aug 7, 2026 |
| Vanguard Capital Management LLC | 1.27M | 3.27% | +13.6K | Aug 13, 2026 |
| Bioimpact Capital LLC | 1.25M | 3.23% | +1.25Mnew | Aug 14, 2026 |
| TCG Crossover Management, LLC | 1.06M | 2.73% | −1.23M | Aug 14, 2026 |
| Wellington Management Group LLP | 954.4K | 2.46% | −80.4K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Kush Parmarincl. 5AM Partners V, LLC, 5AM Opportunities I, L.P. +4 more | 10.80% | 4.12M | 13D | Nov 18, 2025 ↗ |
| Roche Finance Ltd | 6.90% | 2.57M | 13G | Feb 14, 2025 ↗ |
| BlackRock, Inc. | 5.30% | 1.97M | 13G | Feb 4, 2025 ↗ |
| TCG Crossover GP I, LLC | 5.00% | 1.92M | 13G | Nov 25, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 10 percent owner | 4.32M | 11.12% | Aug 26, 2026 |
| 5AM Ventures V, L.P. | 10 percent owner | 3.88M | 9.99% | Aug 10, 2026 |
| Kush Parmar | director | 2.69M | 6.93% | Aug 10, 2026 |
| Dipal Doshi | director, officer: CEO | 526.0K | 1.35% | Mar 3, 2026 |
| Baker Bros. Advisors LP | 10 percent owner | 380.2K | 0.98% | Nov 24, 2025 |
| Natarajan Sethuraman | officer: President, Research & Develop. | 216.3K | 0.56% | May 4, 2026 |
| Nathan J. Dowden | officer: President & COO | 198.6K | 0.51% | May 4, 2026 |
| Kory James Wentworth | officer: Chief Financial Officer | 119.0K | 0.31% | Apr 2, 2026 |
| Peter S. Kim | director | 117.4K | 0.30% | Jun 18, 2025 |
| Bernhardt G. Zeiher | director | 5.0K | 0.01% | May 21, 2026 |
6 ten-percent owners hold 15.84M shares by Form 4, outside the officers-and-directors figure above · 4 people have not refiled in the last 18 months (8.34M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 14,569 | $7.06 | 4,318,348 |
| Aug 25, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 26,522 | $7.54 | 4,332,917 |
| Aug 24, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 21,623 | $7.34 | 4,359,439 |
| Aug 26, 2026 | Bioventures 2018 L.p. Mpm10 percent owner | Sale | 14,569 | $7.06 | 4,318,348 |
| Aug 25, 2026 | Bioventures 2018 L.p. Mpm10 percent owner | Sale | 26,522 | $7.54 | 4,332,917 |
| Aug 24, 2026 | Bioventures 2018 L.p. Mpm10 percent owner | Sale | 21,623 | $7.34 | 4,359,439 |
| Aug 7, 2026 | 5AM Ventures V, L.P.10 percent owner | Sale | 52,317 | $6.85 | 2,783,781 |
| Aug 6, 2026 | 5AM Ventures V, L.P.10 percent owner | Sale | 10,494 | $7.00 | 2,836,098 |
| Aug 10, 2026 | Kush Parmardirector | Sale | 92,444 | $7.00 | 2,691,337 |
| Aug 7, 2026 | Kush Parmardirector | Sale | 52,317 | $6.85 | 2,783,781 |
CongressHouse and Senate disclosures
Not reported.